What Spexis does

Spexis AG is a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of macrocycle therapeutics addressing high unmet medical needs in oncology, respiratory disease, and infectious disease. The company's core technology is an Intelligent Macrocycles platform built on two proprietary, complementary libraries — PEMFinder® (Protein Epitope Mimetics) for modulating protein-protein interactions through β-turn, β-hairpin, and α-helix mimetics, and MacroFinder® (non-peptidic macrocycles) engineered for oral bioavailability and cell permeability. A Structural Crosstalk architecture links the two libraries to transform peptidic hits into non-peptidic scaffolds with improved pharmacokinetics, and an AI/ML layer is applied to enumerate and virtually screen virtual libraries derived from both platforms.

The platform has produced three clinical-stage candidates supported by more than 20 completed clinical trials: Balixafortide, a CXCR4 inhibitor tested in roughly 500 subjects across Phase 1-3 and being developed for pancreatic ductal adenocarcinoma in partnership with the Phase One Foundation; Lonodelestat, a pico-molar neutrophil elastase inhibitor Phase 2-ready for inhaled respiratory use; and Murepavadin, a novel OMPTA-class antibiotic targeting resistant Pseudomonas aeruginosa that has completed nine clinical trials. ColiFin, an inhaled antibiotic for cystic fibrosis lung infections, is advancing into Phase 3 development. Spexis was formed in 2021 through a reverse merger of Enbiotix, Inc. and Polyphor AG, with Polyphor having previously executed the largest Swiss biotech IPO in 2018 at CHF 165 million.

The business model is enterprise B2B licensing and co-development targeting large pharmaceutical and biotechnology companies, supplemented by non-dilutive grant funding from organizations including CARB-X, the Cystic Fibrosis Foundation, the Phase One Foundation, and structured debt/equity from SPRIM Global Investments. Revenue, where generated, is expected to take the form of upfront payments, development milestones, and royalties from licensing deals rather than direct product commercialization. Spexis maintains a small operational footprint of 11-50 employees at a laboratory facility in Allschwil, Switzerland, and reaches customers through industry conferences (notably BIO) and direct partnership inquiries — a model explicitly described by the company as enterprise field sales. The company is listed on the SIX Swiss Exchange under the ticker SPEX.

Name

Spexis

Legal name

Spexis AG

Website

https://spexisbio.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Spexis AG is a Swiss clinical-stage biopharmaceutical company developing macrocycle therapeutics for oncology, respiratory disease, and antibiotic-resistant infections. It licenses and co-develops PEMFinder®- and MacroFinder®-derived clinical candidates (Balixafortide, Lonodelestat, Murepavadin, ColiFin) with large pharmaceutical and biotech partners.

Ownership category

akta.pro rank

Product category

Macrocycle Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• Macrocycle therapeutics
• Drug discovery platform
• Peptide mimetics
• Clinical-stage biopharmaceuticals
• Antibiotic development

Headquarters

HQ city

Allschwil

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Licensing and Co-development Partnerships: Spexis seeks to secure corporate and/or investment partners for each clinical program. Revenue likely generated through upfront payments, milestone payments, and royalties from licensing agreements with pharmaceutical partners.
2. Clinical Development Partnership Funding: Partnership with SGI to fund up to half of Phase 3 development costs through debt facility and investment structures.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Spexis is a Swiss clinical-stage biopharmaceutical company developing macrocycle-based therapeutics through proprietary PEMFinder® (protein epitope mimetics) and MacroFinder® (non-peptidic macrocycles) libraries. The company focuses on discovering and advancing drug candidates for oncology (Balixafortide, CXCR4 inhibitor), respiratory disease (Lonodelestat, neutrophil elastase inhibitor), and resistant infections (Murepavadin, novel antibiotic), with three clinical-stage assets advanced through approximately 20 clinical trials. Spexis also offers its macrocycle platform technology for drug discovery partnerships and licensing.

Product overview

Cyaris operates as a macrocycle-based drug discovery platform centered around two proprietary macrocycle libraries—PEMFinder® (protein epitope mimetics) and MacroFinder® (non-peptidic macrocycles)—which work synergistically to enable hit discovery and optimization for both extra- and intracellular targets including protein-protein interactions. The platform has generated three clinical-stage candidates: Balixafortide (CXCR4 inhibitor for oncology), Lonodelestat (neutrophil elastase inhibitor for respiratory diseases), and Murepavadin (novel antibiotic for resistant infections), with 20 clinical trials completed across these assets. The platform also leverages structural crosstalk between the two libraries and employs AI/ML-driven virtual screening for library expansion and hit-to-lead optimization.

Differentiator

Problem solved

Functional benefit

Products and services

• Balixafortide (BLX) A best-in-class CXCR4 inhibitor clinical candidate developed for oncology indications including pancreatic ductal adenocarcinoma (PDAC), with eight completed clinical trials across Phase 1-3 totaling approximately 500 subjects. It is also being investigated for potential applications in metastatic breast cancer, colorectal cancer, and prostate cancer.
• Lonodelestat A highly potent, reversible neutrophil elastase inhibitor with pico-molar range activity (Ki 0.05 nM), Phase 2 ready for inhaled treatment of respiratory conditions. It is active against both free and membrane-bound neutrophil elastase while preserving innate host bacterial defense.
• Murepavadin A novel bactericidal antibiotic with a new mode of action targeting the outer membrane protein LptD (OMPTA), with P. aeruginosa specificity that preserves the microbiome, potent activity including against MDR/XDR strains, low resistance potential, and no cross-resistance with other antibiotics. Nine clinical trials have been completed covering Phase 1-3.
• ColiFin An inhaled treatment for lung infections in cystic fibrosis patients, advanced into Phase 3 development through a clinical trial partnership with SPRIM Global Investments (SGI) covering up to half of development costs.
• PEMFinder® Macrocycle Library A Protein Epitope Mimetics macrocycle library comprised of highly diverse, single, purified, well-characterized, ready-to-screen macrocycles leveraging non-biologic synthetic chemistry strategies with novel structure-inducing building blocks that mimic protein epitopes such as β-turns, β-hairpins, and α-helices commonly involved in modulating protein-protein interactions.
• MacroFinder® Macrocycle Library A non-peptidic macrocycle library of highly diverse, single, purified, well-characterized, ready-to-screen compounds synthesized using strategically designed building blocks carrying multiple side-chain substituents, optimized for oral bioavailability and cell permeability by mimicking arrangements observed in natural peptide/protein ligands and transforming natural peptide/protein ligand motifs into small-molecule context.

Quantifiable outcome

• 20+ clinical trials conducted with three clinical candidates
• +3 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Bicycle Therapeutics: Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of bicyclic peptides (Bicycles®) — the most direct comparable to Spexis's macrocycle drug discovery platform. Both companies focus on chemically-constrained peptides/macrocycles to address challenging targets including protein-protein interactions, and both target oncology as a lead indication.
• Cyclerion Therapeutics: Cyclerion Therapeutics develops therapeutics using a proprietary small-molecule platform targeting soluble guanylate cyclase (sGC). Like Spexis, it is a small clinical-stage company that emerged from a larger organization's spinout, with comparable headcount, public-market exposure, and reliance on partnership monetization.
• Ra Pharmaceuticals (acquired by UCB): Ra Pharmaceuticals developed a platform of macrocyclic peptides (including zilucoplan, later acquired by UCB for ~$2.5B) and represents a direct strategic analog to Spexis — a small-cap macrocycle platform that achieved a high-value pharma acquisition. The acquisition path is the primary bull-case template for Spexis's macrocycle programs.
• Protagonist Therapeutics: Protagonist Therapeutics develops peptide-based therapeutics using a proprietary technology platform targeting protein-protein interactions. It shares Spexis's focus on constrained peptides for challenging targets and operates with a similar clinical-stage, partnership-oriented business model.
• Crinetics Pharmaceuticals: Crinetics Pharmaceuticals develops peptide-based therapeutics with a focus on endocrine and metabolic diseases. Comparable in size, clinical stage, and reliance on proprietary peptide chemistry platforms to develop differentiated therapeutics for challenging targets.
• PeptiDream: PeptiDream is a Japanese biopharmaceutical company that operates one of the leading constrained/cyclic peptide discovery platforms. It pursues a similar licensing-and-co-development business model with major pharma and represents a direct competitor in the macrocycle/constrained peptide discovery space.

Broad incumbents

• UCB (acquirer of Ra Pharma): UCB acquired Ra Pharmaceuticals to gain its macrocyclic peptide platform and complement its own peptide capabilities. UCB represents the type of strategic acquirer that could purchase Spexis to obtain validated macrocycle assets and platform technology in a single transaction.
• Ferring Pharmaceuticals: Ferring Pharmaceuticals is a research-driven specialty biopharmaceutical company with established expertise in peptide therapeutics (e.g., branded peptides in reproductive health and gastroenterology). It is a logical potential commercial partner or acquirer for Spexis's ColiFin (inhaled antibiotic) program.
• Asahi Kasei Pharma: Asahi Kasei Pharma acquired Spexis co-founder Jeff Wager's previous company, Artisan Pharma, in 2011. As a larger specialty pharma player with specialty therapeutic focus, it represents the type of strategic acquirer that has historically executed deals for Spexis-affiliated assets.

Others

• Achaogen: Achaogen was a clinical-stage biopharmaceutical company that historically developed Murepavadin-like novel antibiotics targeting resistant Gram-negative bacteria. While it ultimately failed, it provides a relevant historical reference for the challenges and investor expectations in the novel antibiotic space where Spexis's Murepavadin competes.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/polyphor
• LinkedInlinkedin.com/company/polyphor-ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds11 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Spexis